CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript

PresentationI would now like to turn the conference over to Natasha Wagner. You may begin.Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions]Natasha Moshirian Wagner Hello, and thank you for joining us. I'm Natasha Wagner, VP of Corporate Communications at CareDx. Welcome to our investor webcast focused on AlloHeme, advancing AI-enabled relapse monitoring in AML and MDS post-cell therapy, positioning CareDx to lead ...